Combined modality treatment in the management of high-risk prostate cancer

The efficacy of a multimodality protocol using neoadjuvant and concomitant hormonal therapy, brachytherapy, and three-dimensional conformal external beam radiotherapy (RT) in high-risk prostate cancer was evaluated using biochemical outcomes and posttreatment biopsy results. Between February 1994 an...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	International journal of radiation oncology, biology, physics Ročník 59; číslo 5; s. 1352
Hlavní autori:	Stock, Richard G, Cahlon, Oren, Cesaretti, Jamie A, Kollmeier, Marisa A, Stone, Nelson N
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.08.2004
Predmet:	Androgen Antagonists - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Brachytherapy Combined Modality Therapy Finasteride - therapeutic use Flutamide - therapeutic use Gonadotropin-Releasing Hormone - agonists Humans Male Palladium - therapeutic use Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy Radioisotopes - therapeutic use Radiotherapy, Conformal Testosterone - blood
ISSN:	0360-3016
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	The efficacy of a multimodality protocol using neoadjuvant and concomitant hormonal therapy, brachytherapy, and three-dimensional conformal external beam radiotherapy (RT) in high-risk prostate cancer was evaluated using biochemical outcomes and posttreatment biopsy results. Between February 1994 and November 1999, 132 high-risk patients were treated with combined hormonal therapy (9 months), permanent radioactive seed brachytherapy, and external beam RT, with follow-up ranging from 36 to 88 months (median, 50 months). The eligibility criteria were any of the following: Gleason score 8-10, initial prostate-specific antigen (PSA) level >20 ng/mL, clinical Stage T2c-T3, or positive seminal vesicle biopsy, or two or more of the following: Gleason score 7, PSA level >10-20 ng/mL, or Stage T2b. Twenty percent of patients had a positive seminal vesicle biopsy before therapy. Negative laparoscopic pelvic lymph node dissections were performed in 44% of patients. The actuarial overall freedom from PSA failure rate was 86% at 5 years. The freedom from PSA failure rate at 5 years was 97% for those with a Gleason score of < or =6 (35 of 36), 85% for a Gleason score of 7 (50 of 59), and 76% for a Gleason score of 8-10 (28 of 37; p = 0.03). A trend was noted toward worse outcomes in seminal vesicle biopsy-positive patients, with a 5-year freedom from PSA failure rate of 74% vs. 89% for all other patients (p = 0.06). Posttreatment prostate biopsies were performed in 47 patients and were negative in 96% at the first biopsy and 100% at the last biopsy. Trimodality therapy with androgen suppression, brachytherapy, and external beam RT for high-risk prostate cancer results in excellent biochemical and pathologically confirmed local control.
AbstractList	The efficacy of a multimodality protocol using neoadjuvant and concomitant hormonal therapy, brachytherapy, and three-dimensional conformal external beam radiotherapy (RT) in high-risk prostate cancer was evaluated using biochemical outcomes and posttreatment biopsy results.PURPOSEThe efficacy of a multimodality protocol using neoadjuvant and concomitant hormonal therapy, brachytherapy, and three-dimensional conformal external beam radiotherapy (RT) in high-risk prostate cancer was evaluated using biochemical outcomes and posttreatment biopsy results.Between February 1994 and November 1999, 132 high-risk patients were treated with combined hormonal therapy (9 months), permanent radioactive seed brachytherapy, and external beam RT, with follow-up ranging from 36 to 88 months (median, 50 months). The eligibility criteria were any of the following: Gleason score 8-10, initial prostate-specific antigen (PSA) level >20 ng/mL, clinical Stage T2c-T3, or positive seminal vesicle biopsy, or two or more of the following: Gleason score 7, PSA level >10-20 ng/mL, or Stage T2b. Twenty percent of patients had a positive seminal vesicle biopsy before therapy. Negative laparoscopic pelvic lymph node dissections were performed in 44% of patients.METHODS AND MATERIALSBetween February 1994 and November 1999, 132 high-risk patients were treated with combined hormonal therapy (9 months), permanent radioactive seed brachytherapy, and external beam RT, with follow-up ranging from 36 to 88 months (median, 50 months). The eligibility criteria were any of the following: Gleason score 8-10, initial prostate-specific antigen (PSA) level >20 ng/mL, clinical Stage T2c-T3, or positive seminal vesicle biopsy, or two or more of the following: Gleason score 7, PSA level >10-20 ng/mL, or Stage T2b. Twenty percent of patients had a positive seminal vesicle biopsy before therapy. Negative laparoscopic pelvic lymph node dissections were performed in 44% of patients.The actuarial overall freedom from PSA failure rate was 86% at 5 years. The freedom from PSA failure rate at 5 years was 97% for those with a Gleason score of < or =6 (35 of 36), 85% for a Gleason score of 7 (50 of 59), and 76% for a Gleason score of 8-10 (28 of 37; p = 0.03). A trend was noted toward worse outcomes in seminal vesicle biopsy-positive patients, with a 5-year freedom from PSA failure rate of 74% vs. 89% for all other patients (p = 0.06). Posttreatment prostate biopsies were performed in 47 patients and were negative in 96% at the first biopsy and 100% at the last biopsy.RESULTSThe actuarial overall freedom from PSA failure rate was 86% at 5 years. The freedom from PSA failure rate at 5 years was 97% for those with a Gleason score of < or =6 (35 of 36), 85% for a Gleason score of 7 (50 of 59), and 76% for a Gleason score of 8-10 (28 of 37; p = 0.03). A trend was noted toward worse outcomes in seminal vesicle biopsy-positive patients, with a 5-year freedom from PSA failure rate of 74% vs. 89% for all other patients (p = 0.06). Posttreatment prostate biopsies were performed in 47 patients and were negative in 96% at the first biopsy and 100% at the last biopsy.Trimodality therapy with androgen suppression, brachytherapy, and external beam RT for high-risk prostate cancer results in excellent biochemical and pathologically confirmed local control.CONCLUSIONTrimodality therapy with androgen suppression, brachytherapy, and external beam RT for high-risk prostate cancer results in excellent biochemical and pathologically confirmed local control. The efficacy of a multimodality protocol using neoadjuvant and concomitant hormonal therapy, brachytherapy, and three-dimensional conformal external beam radiotherapy (RT) in high-risk prostate cancer was evaluated using biochemical outcomes and posttreatment biopsy results. Between February 1994 and November 1999, 132 high-risk patients were treated with combined hormonal therapy (9 months), permanent radioactive seed brachytherapy, and external beam RT, with follow-up ranging from 36 to 88 months (median, 50 months). The eligibility criteria were any of the following: Gleason score 8-10, initial prostate-specific antigen (PSA) level >20 ng/mL, clinical Stage T2c-T3, or positive seminal vesicle biopsy, or two or more of the following: Gleason score 7, PSA level >10-20 ng/mL, or Stage T2b. Twenty percent of patients had a positive seminal vesicle biopsy before therapy. Negative laparoscopic pelvic lymph node dissections were performed in 44% of patients. The actuarial overall freedom from PSA failure rate was 86% at 5 years. The freedom from PSA failure rate at 5 years was 97% for those with a Gleason score of < or =6 (35 of 36), 85% for a Gleason score of 7 (50 of 59), and 76% for a Gleason score of 8-10 (28 of 37; p = 0.03). A trend was noted toward worse outcomes in seminal vesicle biopsy-positive patients, with a 5-year freedom from PSA failure rate of 74% vs. 89% for all other patients (p = 0.06). Posttreatment prostate biopsies were performed in 47 patients and were negative in 96% at the first biopsy and 100% at the last biopsy. Trimodality therapy with androgen suppression, brachytherapy, and external beam RT for high-risk prostate cancer results in excellent biochemical and pathologically confirmed local control.
Author	Stone, Nelson N Cahlon, Oren Kollmeier, Marisa A Stock, Richard G Cesaretti, Jamie A
Author_xml	– sequence: 1 givenname: Richard G surname: Stock fullname: Stock, Richard G email: r.stock@mssm.edu organization: Department of Radiation Oncology, Mount Sinai School of Medicine, Box 1236, 1184 5th Avenue, New York, NY 10029, USA. r.stock@mssm.edu – sequence: 2 givenname: Oren surname: Cahlon fullname: Cahlon, Oren – sequence: 3 givenname: Jamie A surname: Cesaretti fullname: Cesaretti, Jamie A – sequence: 4 givenname: Marisa A surname: Kollmeier fullname: Kollmeier, Marisa A – sequence: 5 givenname: Nelson N surname: Stone fullname: Stone, Nelson N
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/15275720$$D View this record in MEDLINE/PubMed
BookMark	eNo1j8tOwzAURL0oog_4A4S8Ypdw7SR2skQVT1ViA-voxrlpXBKn2O6if08FZTXS6OiMZslmbnLE2I2AVIBQ97vU7vzU7FMJkKcgUpDZjC0gU5BkJ2DOliHsAEAInV-yuSikLrSEBXtbT2NjHbV8nFocbDzy6AnjSC5y63jsiY_ocEu_zdTx3m77xNvwxfd-ChEjcYPOkL9iFx0Oga7PuWKfT48f65dk8_78un7YJKYAHRNFjTZtJkvSoqwajVhVQmdFZaBsTFYZ1UCHpSgKlHlRQllpJCEkZNApbEGu2N2f97T_faAQ69EGQ8OAjqZDqJXSuciVPoG3Z_DQjNTWe29H9Mf6_738AeOOXX0
CitedBy_id	crossref_primary_10_1016_j_hoc_2013_08_006 crossref_primary_10_1016_j_ijrobp_2008_04_031 crossref_primary_10_1016_j_prro_2011_11_001 crossref_primary_10_1186_1748_717X_9_13 crossref_primary_10_1016_j_brachy_2010_10_002 crossref_primary_10_1586_14737140_6_11_1639 crossref_primary_10_1016_j_ijrobp_2008_10_027 crossref_primary_10_1016_j_canrad_2005_09_019 crossref_primary_10_1016_j_ijrobp_2011_06_2013 crossref_primary_10_1016_S0210_4806_06_73551_3 crossref_primary_10_1016_j_ijrobp_2010_06_015 crossref_primary_10_1016_j_ijrobp_2008_04_038 crossref_primary_10_1016_j_urology_2004_12_039 crossref_primary_10_1016_j_ijrobp_2009_02_069 crossref_primary_10_1016_j_ijrobp_2006_05_072 crossref_primary_10_1002_cncr_22560 crossref_primary_10_1002_cncr_27784 crossref_primary_10_1177_1660_18170 crossref_primary_10_1016_j_ijrobp_2005_09_005 crossref_primary_10_1016_j_brachy_2011_01_004 crossref_primary_10_1016_j_brachy_2016_12_015 crossref_primary_10_1038_ncponc1224 crossref_primary_10_1002_cncr_22810 crossref_primary_10_1016_j_brachy_2006_11_002 crossref_primary_10_1118_1_3685582 crossref_primary_10_1016_j_brachy_2006_09_003 crossref_primary_10_1016_j_canrad_2008_09_003 crossref_primary_10_1016_j_ijrobp_2007_11_056 crossref_primary_10_1002_cncr_26203 crossref_primary_10_1097_COC_0000000000000915 crossref_primary_10_1007_s11604_021_01189_3 crossref_primary_10_3816_CGC_2006_n_016 crossref_primary_10_1016_j_ijrobp_2008_10_071 crossref_primary_10_1016_j_brachy_2020_07_006 crossref_primary_10_1016_j_ijrobp_2009_01_078 crossref_primary_10_1155_2010_471375 crossref_primary_10_1016_j_ijrobp_2006_05_016 crossref_primary_10_1016_S1548_5315_11_70056_0 crossref_primary_10_1111_j_1464_410X_2009_08661_x crossref_primary_10_1007_s00261_025_04858_3 crossref_primary_10_1016_j_juro_2009_09_084 crossref_primary_10_1200_JCO_2009_26_5579 crossref_primary_10_1016_j_ijrobp_2010_08_045 crossref_primary_10_1016_j_ijrobp_2005_07_981 crossref_primary_10_1097_COC_0b013e318145b9ba crossref_primary_10_1016_j_brachy_2016_06_003 crossref_primary_10_1038_s41585_018_0060_7 crossref_primary_10_1016_j_ijrobp_2006_11_046 crossref_primary_10_1016_j_juro_2006_06_079 crossref_primary_10_1016_S1548_5315_11_70943_3 crossref_primary_10_1016_j_juro_2006_10_018 crossref_primary_10_1016_j_urolonc_2009_09_002 crossref_primary_10_1016_j_brachy_2009_01_002 crossref_primary_10_1016_S1359_6349_05_80291_5 crossref_primary_10_1016_j_clon_2008_09_003 crossref_primary_10_1038_aja_2011_121 crossref_primary_10_1016_j_canrad_2009_10_003 crossref_primary_10_1016_j_brachy_2014_08_046 crossref_primary_10_1016_j_urology_2005_08_023 crossref_primary_10_1186_s13014_017_0932_7 crossref_primary_10_1016_j_juro_2007_01_069 crossref_primary_10_1111_iju_15609 crossref_primary_10_1016_j_brachy_2012_07_002 crossref_primary_10_1016_j_ijrobp_2008_08_049 crossref_primary_10_1016_j_brachy_2008_04_002 crossref_primary_10_1016_S1001_9294_15_30038_9 crossref_primary_10_1016_j_juro_2009_10_006 crossref_primary_10_1016_j_urology_2006_09_045 crossref_primary_10_1007_s12094_010_0516_6 crossref_primary_10_1016_j_ijrobp_2009_01_059
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.ijrobp.2004.01.023
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
ExternalDocumentID	15275720
Genre	Clinical Trial Clinical Trial, Phase II Journal Article
GroupedDBID	--- --K .55 .GJ 0R~ 1B1 1RT 1~5 29J 4.4 457 4G. 53G 5RE 5VS 7-5 AAEDT AAEDW AAQFI AAQQT AAWTL AAXUO ABJNI ABLJU ABNEU ABOCM ABUDA ABWVN ACGFS ACIUM ACRPL ADBBV ADMUD ADNMO ADPAM ADVLN AENEX AFCTW AFFNX AFTJW AGRDE AHHHB AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY CGR CUY CVF DU5 EBS ECM EFJIC EIF EJD F5P FDB FIRID HED HMO HZ~ IHE J1W KOM LX3 M41 MO0 NPM NQ- O9- RIG RNS ROL RPZ SDG SEL SES SSZ UDS UV1 X7M XH2 ~S- 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS
ID	FETCH-LOGICAL-c507t-6eb7cd328e7189b7aa9917359c08bc39c6b0fa8155a24580897ae112030f6ad02
IEDL.DBID	7X8
ISICitedReferencesCount	76
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000222932800013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0360-3016
IngestDate	Sun Nov 09 14:31:28 EST 2025 Wed Feb 19 01:54:21 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	5
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c507t-6eb7cd328e7189b7aa9917359c08bc39c6b0fa8155a24580897ae112030f6ad02
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23
PMID	15275720
PQID	66741467
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_66741467 pubmed_primary_15275720
PublicationCentury	2000
PublicationDate	2004-08-01
PublicationDateYYYYMMDD	2004-08-01
PublicationDate_xml	– month: 08 year: 2004 text: 2004-08-01 day: 01
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	International journal of radiation oncology, biology, physics
PublicationTitleAlternate	Int J Radiat Oncol Biol Phys
PublicationYear	2004
SSID	ssj0001174
Score	2.104479
Snippet	The efficacy of a multimodality protocol using neoadjuvant and concomitant hormonal therapy, brachytherapy, and three-dimensional conformal external beam...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1352
SubjectTerms	Androgen Antagonists - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Brachytherapy Combined Modality Therapy Finasteride - therapeutic use Flutamide - therapeutic use Gonadotropin-Releasing Hormone - agonists Humans Male Palladium - therapeutic use Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - drug therapy Prostatic Neoplasms - radiotherapy Radioisotopes - therapeutic use Radiotherapy, Conformal Testosterone - blood
Title	Combined modality treatment in the management of high-risk prostate cancer
URI	https://www.ncbi.nlm.nih.gov/pubmed/15275720 https://www.proquest.com/docview/66741467
Volume	59
WOSCitedRecordID	wos000222932800013&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NS8NAEB2qFfHi90f93IPXhTS7yW5AEBGLiC09qPQWNptdqNAkttXf7-wmqSfx4CW3QBhm37zNvHkDcJ1HmnOrQmqE5ZQro6nUNqPSxpZjAVLWj4-9PYvRSE4mybgDN-0sjJNVtpjogTovtftH7rb2cXeqb6sP6nZGud5qs0BjDboMiYzLaTH58QrvNx7MLEakQWbTDs55ddf0fV5m3q-S17ad7HeK6UvNYOd_H7kL2w3FJHd1TuxBxxT7sDlsmugH8IQYgPdhk5NZmXsaTlZyczItCFJCMlupYkhpifM0pk6ETio3JIL0lGiXLfNDeB08vNw_0malAtVI_JY0NpnQOQulwZqUZEIp5IeCRYkOZKZZouMssEoiyVAhj2QgE6EMUjKEAhurPAiPYL0oC3MCpI8XjSgSSSB1wFXEFOd5X0kTKomoYZMeXLUxSjFlXR9CFab8XKRtlHpwXIc5rWpnjdTt2I1EGJz--e4ZbNUaGifFO4euxcNqLmBDfy2ni_mlzwR8jsbDb-z7vVc
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Combined+modality+treatment+in+the+management+of+high-risk+prostate+cancer&rft.jtitle=International+journal+of+radiation+oncology%2C+biology%2C+physics&rft.au=Stock%2C+Richard+G&rft.au=Cahlon%2C+Oren&rft.au=Cesaretti%2C+Jamie+A&rft.au=Kollmeier%2C+Marisa+A&rft.date=2004-08-01&rft.issn=0360-3016&rft.volume=59&rft.issue=5&rft.spage=1352&rft_id=info:doi/10.1016%2Fj.ijrobp.2004.01.023&rft_id=info%3Apmid%2F15275720&rft_id=info%3Apmid%2F15275720&rft.externalDocID=15275720
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0360-3016&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0360-3016&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0360-3016&client=summon